Literature DB >> 20854973

Frequency and age-related course of mitral valve dysfunction in the Marfan syndrome.

Meike Rybczynski1, Thomas S Mir, Sara Sheikhzadeh, Alexander M J Bernhardt, Claudia Schad, Hendrik Treede, Simon Veldhoen, Eike F Groene, Kristin Kühne, Dietmar Koschyk, Peter N Robinson, Jürgen Berger, Hermann Reichenspurner, Thomas Meinertz, Yskert von Kodolitsch.   

Abstract

Mitral valve (MV) prolapse (MVP) has a high prevalence of 2% to 3% in the general population and thus constitutes the most common cause of severe nonischemic MV regurgitation (MVR). MVP is also common in persons with the Marfan syndrome. However, to date, a large-scale population-based cohort study using modern echocardiographic techniques has not been performed, and the frequency of MVP and the relation of MV dysfunction and age have not been investigated. Therefore, we conducted a population-based cohort study of 204 patients (108 males and 96 females, aged 31.2 ± 16.4 years) with classic Marfan syndrome. We performed echocardiographic follow-up of 174 patients for a mean of 4.4 ± 4.3 years. On the initial or subsequent echocardiographic scan, MVP was present in 82 patients (40%), severe MVR in 25 (12%), and MV endocarditis in 5 patients (2.5%). At 30 years of age, the Weibull cumulative distribution was 42.6% (95% confidence interval [CI] 36% to 50%) for MVP, 56.5% (95% CI 49.3% to 64%) for MVR of any degree, 6.7% (95% CI 3.9% to 11.3%) for severe MVR, and 0.92% (95% CI 0.21% to 3.91%) for MV endocarditis. The cumulative hazard for severe MVR and MV endocarditis was estimated to increase with age. MVP was associated with dural ectasia (p = 0.01), ectopia lentis (p = 0.02), and skeletal involvement (p <0.001). Severe MVR was related to tricuspid valve prolapse (p = 0.002) and to the sporadic form of the Marfan syndrome (p = 0.006). In conclusion, MVP was comparatively frequent in patients with the Marfan syndrome and carries an increased risk of progression to severe MVR and endocarditis, especially in older adults.
Copyright © 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20854973     DOI: 10.1016/j.amjcard.2010.05.038

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  23 in total

1.  [Cardiological diseases].

Authors:  L Gross; S Massberg; D Sibbing
Journal:  Internist (Berl)       Date:  2013-10       Impact factor: 0.743

2.  Genetic diagnostics of inherited aortic diseases : Medical strategy analysis.

Authors:  Y von Kodolitsch; K Kutsche
Journal:  Herz       Date:  2017-08       Impact factor: 1.443

Review 3.  Cardiovascular Management of Adults with Marfan Syndrome.

Authors:  Yukiko Isekame; Sabiha Gati; Jose Antonio Aragon-Martin; Rachel Bastiaenen; Sreenivasa Rao Kondapally Seshasai; Anne Child
Journal:  Eur Cardiol       Date:  2016-12

4.  Non-aortic cardiovascular disease in Marfan syndrome: a nationwide epidemiological study.

Authors:  Niels H Andersen; Kristian A Groth; Agnethe Berglund; Hanne Hove; Claus H Gravholt; Kirstine Stochholm
Journal:  Clin Res Cardiol       Date:  2021-04-22       Impact factor: 5.460

5.  Associations of Age and Sex With Marfan Phenotype: The National Heart, Lung, and Blood Institute GenTAC (Genetically Triggered Thoracic Aortic Aneurysms and Cardiovascular Conditions) Registry.

Authors:  Mary J Roman; Richard B Devereux; Liliana R Preiss; Federico M Asch; Kim A Eagle; Kathryn W Holmes; Scott A LeMaire; Cheryl L Maslen; Dianna M Milewicz; Shaine A Morris; Siddharth K Prakash; Reed E Pyeritz; William J Ravekes; Ralph V Shohet; Howard K Song; Jonathan W Weinsaft
Journal:  Circ Cardiovasc Genet       Date:  2017-06

6.  Cardiothoracic surgery and peripheral endovascular intervention in cardiovascular damage from a cohort of orphan rheumatological diseases-epidemiological and survival analysis.

Authors:  Maria Elena Soto; Huitzilihuitl Saucedo-Orozco; Eric Ochoa-Hein; Guering Eid-Lidt; Javier E Anaya-Ayala; Israel Pérez-Torres; Solange Gabriela Koretzky; Pedro A Reyes; Edison Ricardo Espinoza-Saquicela; Ivan Hernandez; Humberto Martinez-Hernandez
Journal:  J Thorac Dis       Date:  2022-06       Impact factor: 3.005

Review 7.  Perspectives on the revised Ghent criteria for the diagnosis of Marfan syndrome.

Authors:  Yskert von Kodolitsch; Julie De Backer; Helke Schüler; Peter Bannas; Cyrus Behzadi; Alexander M Bernhardt; Mathias Hillebrand; Bettina Fuisting; Sara Sheikhzadeh; Meike Rybczynski; Tilo Kölbel; Klaus Püschel; Stefan Blankenberg; Peter N Robinson
Journal:  Appl Clin Genet       Date:  2015-06-16

8.  The economic impact of Marfan syndrome: a non-experimental, retrospective, population-based matched cohort study.

Authors:  Dmitrij Achelrod; Carl Rudolf Blankart; Roland Linder; Yskert von Kodolitsch; Tom Stargardt
Journal:  Orphanet J Rare Dis       Date:  2014-06-23       Impact factor: 4.123

9.  Association of Mitral Annular Disjunction With Cardiovascular Outcomes Among Patients With Marfan Syndrome.

Authors:  Anthony Demolder; Frank Timmermans; Mattias Duytschaever; Laura Muiño-Mosquera; Julie De Backer
Journal:  JAMA Cardiol       Date:  2021-10-01       Impact factor: 30.154

Review 10.  The Molecular Genetics of Marfan Syndrome.

Authors:  Qiu Du; Dingding Zhang; Yue Zhuang; Qiongrong Xia; Taishen Wen; Haiping Jia
Journal:  Int J Med Sci       Date:  2021-05-27       Impact factor: 3.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.